The Chinese medicine and health products import and Export Chamber announced the export situation of Chinese medicine and health products in 2017. It said that the import and export volume of Chinese medicines and health products amounted to 116 billion 676 million US dollars, up 12.64% over the same period last year.
However, in the growth situation, the number of trade frictions encountered by China's pharmaceutical trade has increased significantly. The new round of international industrial competition is more intense, and some other emerging economies have lower capacity to pay. At the same time, the global economy is generally recovering. The demand for international trade in medicine trade has stabilized and recovered. The export structure of Chinese medicine has been further optimized, and the pace of internationalization of enterprises has been accelerated. New development momentum is taking shape, and the development of pharmaceutical trade is generally improving.
According to the statistics of Chinese customs data, in 2017, the import and export of medical health products in China was 116 billion 676 million US dollars, up 12.64% from the same period. Among them, exports of 60 billion 799 million yuan, reversing the decline last year, an increase of 9.44%, an increase of nearly five years, the highest value, imports 55 billion 877 million U.S. dollars, an increase of 16.34%, the foreign trade surplus of 4 billion 922 million U.S. dollars, down 34.60%. On the whole, in 2017, the demand for international market increased. China's supply reform initially achieved results. The export volume of pharmaceutical exports increased and exports increased steadily. Meanwhile, domestic demand remained at a high level and imports kept fast growth.
According to Chinese medicines and health products import and Export Chamber of Commerce, 2017 Chinese exports rebound, exports amounted to $3 billion 640 million, an increase of 2.07%, plant extracts, active market, exports $2 billion 10 million, an increase of 4.33%, Chinese exports of $250 million, an increase of 11.03%, exports of crude drug and continued negative growth, down 2.23%.
At the same time, the export of Western medicine has also increased significantly. In 2017, the export of Chinese Western medicine products was 35 billion 456 million US dollars, up by 12.62%. Among them, the export of API was $29 billion 117 million, up 13.71% from the same period. As the cost of environmental protection is rising, the supply side is shrinking and the backward production capacity is gradually withdrawn, and the competitive pattern of high quality enterprises is getting better. The export of the preparation was $3 billion 456 million, up 8.32% from the same period.
Exports of medical equipment is still a steady growth trend, in 2017, medical equipment exports amounted to US $21 billion 703 million, an increase of 5.84%, among them, medical dressings, disposable supplies, diagnosis and treatment equipment, rehabilitation equipment, dental equipment to achieve steady growth, increased 2.97%, 9.53%, 4.11%, 6.29%, 17%.
In 2017, the pharmaceutical imports still shows two digit growth, imports of up to $55 billion 877 million, an increase of 16.34%, which ranked first in Chinese pharmaceutical products imported western medicine imports $17 billion 157 million, an increase of 21.66%; the hospital diagnosis and treatment equipment imported $14 billion 631 million, an increase of 9.60%. With “ a priority review of ” the system was formally landed at home, and imported drugs began to piled into the Chinese market.
In the new fields of biomedicine and in vitro diagnosis in 2017, the Chinese medical and health products import and Export Chamber of commerce is considered to be in the ascendant. The production and marketing of China's biopharmaceutical industry has been growing steadily, with an average annual growth rate of more than 15%. China has become the second only to the United States, with the largest number of biodrugs in the country. The market size of China's extracorporeal diagnostic reagents is also expanding. It is expected that by 2019, the market will reach 72 billion 300 million yuan and the annual growth rate will reach 18.7%.
In the situation that the overall export situation is good, the trade frictions are increasing with the vigorous growth of the trade in medical services. The China local enterprises, with the pharmaceutical industry chain extension and segmentation, CRO (R & D outsourcing service contract (Medicine), CMO pharmaceutical production contract outsourcing), CSO (pharmaceutical sales contract outsourcing services) and other new formats gradually rise, become a new form of China pharmaceutical enterprises to participate in the international division of labor. Chinese medicine services accelerate “ go out of ” step. According to the data, about 2000 Chinese medical clinicians are sent every year, accounting for 60% of the total number of medical service personnel assigned to China. More than 60 Chinese medicine trade and service institutions set up TCM hospitals, TCM clinics, health care institutions, Chinese medicine research centers in more than 20 countries and regions. The number of annual visits reached 250 thousand.
News